NCT06595563 - HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

September 30, 2029

Conditions

HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer

Interventions

DRUG

Trastuzumab emtansine

T-DM1 will be administered IV at a dose of 3.6 mg/kg every 3 weeks. (21 days +/- 3 days) until disease progression, unacceptable toxicity or request of the subject to withdraw from the study. The total dose will depend on the subject's weight on day 1 of each T-DM1 cycle.